nicotergoline

Trade name: Sermion

Small moleculeexperimental

Nicergoline, sold under the brand name Sermion among others, is an ergot derivative used to treat senile dementia and other disorders with vascular origins. Internationally it has been used for frontotemporal dementia as well as early onset in Lewy body dementia and Parkinson's dementia. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs. Unlike many other ergolines, such as ergotamine, nicergoline is not associated with cardiac fibrosis. — Wikipedia

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Jan 1, 2015 (NCT02374567)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CO[C@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]1Cc1cn(C)c3cccc2c13
Mol. weight
484.39 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • cergodum
  • duracebrol
  • nicergolent
  • nicergolin
  • nicergolin
  • nicergolina
  • nicergolina
  • nicergoline
  • nicergoline
  • nicergoline
  • nicergoline
  • nicergoline
  • nicergoline
  • nicergoline
  • nicergoline
  • nicergolinum
  • nicergolinum
  • nicotergoline
  • sermion
  • sermion
  • sermion

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02374567Phase 3Jan 1, 2015Gottfried Wilhelm Leibniz Universität Hannover
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital1112015
1 organizations
Page 1 / 1